New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia:
Since the introduction of new anthracycline derivatives and anthrachi none analogues a few years ago, aclacinomycin A (Aclarubicin) has become an established agent for the treatment of hematologic malig nancies. A special symposium was therefore held during the congress of the German Society of He...
Gespeichert in:
| Weitere Verfasser: | , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Berlin, Heidelberg
Springer Berlin Heidelberg
1990
|
| Schlagworte: | |
| Online-Zugang: | UBR01 Volltext |
| Zusammenfassung: | Since the introduction of new anthracycline derivatives and anthrachi none analogues a few years ago, aclacinomycin A (Aclarubicin) has become an established agent for the treatment of hematologic malig nancies. A special symposium was therefore held during the congress of the German Society of Hermatology and Oncology in Hannover in October 1989 to provide an up-to-date overv.iew. Leading experts from the United States, Sweden, and Germany reported on the results being obtained with aclacinomycin A, alone or combined with other agents, in patients with acute leukemias and myelodysplastic syndromes. This book is based on their contributions. As regards single-agent treatment, aclacinomycin A in myelodys plastic syndromes is dealt with, as well as its application in older patients with acute myeloid leukemia. Four contributions are devoted to the use of aclacinomycin A in combination with conventional or intermediate dose cytosine arabinoside or etoposide in patients with relapsed or refractory acute myeloid leukemia. The results reported indicate that aclacinomycin A has substantial activity in the treatment of hematologic malignancies. In summary, this book provides a valuable update on the current status of aclacinomycin A as used by experts in the treatment of he matologic malignancies |
| Beschreibung: | 1 Online-Ressource (IX, 52 p) |
| ISBN: | 9783642757204 |
| DOI: | 10.1007/978-3-642-75720-4 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV046144407 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190905s1990 |||| o||u| ||||||eng d | ||
| 020 | |a 9783642757204 |9 978-3-642-75720-4 | ||
| 024 | 7 | |a 10.1007/978-3-642-75720-4 |2 doi | |
| 035 | |a (ZDB-2-SME)978-3-642-75720-4 | ||
| 035 | |a (OCoLC)1119076175 | ||
| 035 | |a (DE-599)BVBBV046144407 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.994 |2 23 | |
| 245 | 1 | 0 | |a New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia |c edited by W. Hiddemann, R. Mertelsmann |
| 264 | 1 | |a Berlin, Heidelberg |b Springer Berlin Heidelberg |c 1990 | |
| 300 | |a 1 Online-Ressource (IX, 52 p) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 520 | |a Since the introduction of new anthracycline derivatives and anthrachi none analogues a few years ago, aclacinomycin A (Aclarubicin) has become an established agent for the treatment of hematologic malig nancies. A special symposium was therefore held during the congress of the German Society of Hermatology and Oncology in Hannover in October 1989 to provide an up-to-date overv.iew. Leading experts from the United States, Sweden, and Germany reported on the results being obtained with aclacinomycin A, alone or combined with other agents, in patients with acute leukemias and myelodysplastic syndromes. This book is based on their contributions. As regards single-agent treatment, aclacinomycin A in myelodys plastic syndromes is dealt with, as well as its application in older patients with acute myeloid leukemia. Four contributions are devoted to the use of aclacinomycin A in combination with conventional or intermediate dose cytosine arabinoside or etoposide in patients with relapsed or refractory acute myeloid leukemia. The results reported indicate that aclacinomycin A has substantial activity in the treatment of hematologic malignancies. In summary, this book provides a valuable update on the current status of aclacinomycin A as used by experts in the treatment of he matologic malignancies | ||
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Hematology | |
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Hematology | |
| 650 | 0 | 7 | |a Myelose |0 (DE-588)4170926-3 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Aclarubicin |0 (DE-588)4243689-8 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)1071861417 |a Konferenzschrift |y 1989 |z Hannover |2 gnd-content | |
| 689 | 0 | 0 | |a Myelose |0 (DE-588)4170926-3 |D s |
| 689 | 0 | 1 | |a Aclarubicin |0 (DE-588)4243689-8 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Hiddemann, W. |4 edt | |
| 700 | 1 | |a Mertelsmann, R. |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783540526131 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783642757211 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-3-642-75720-4 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_1990/2004 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-031524592 | ||
| 966 | e | |u https://doi.org/10.1007/978-3-642-75720-4 |l UBR01 |p ZDB-2-SME |q ZDB-2-SME_1990/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804180479748866048 |
|---|---|
| any_adam_object | |
| author2 | Hiddemann, W. Mertelsmann, R. |
| author2_role | edt edt |
| author2_variant | w h wh r m rm |
| author_facet | Hiddemann, W. Mertelsmann, R. |
| building | Verbundindex |
| bvnumber | BV046144407 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-3-642-75720-4 (OCoLC)1119076175 (DE-599)BVBBV046144407 |
| dewey-full | 616.994 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.994 |
| dewey-search | 616.994 |
| dewey-sort | 3616.994 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-3-642-75720-4 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03134nmm a2200505zc 4500</leader><controlfield tag="001">BV046144407</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190905s1990 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783642757204</subfield><subfield code="9">978-3-642-75720-4</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-3-642-75720-4</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-3-642-75720-4</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1119076175</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046144407</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.994</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia</subfield><subfield code="c">edited by W. Hiddemann, R. Mertelsmann</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Berlin, Heidelberg</subfield><subfield code="b">Springer Berlin Heidelberg</subfield><subfield code="c">1990</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (IX, 52 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Since the introduction of new anthracycline derivatives and anthrachi none analogues a few years ago, aclacinomycin A (Aclarubicin) has become an established agent for the treatment of hematologic malig nancies. A special symposium was therefore held during the congress of the German Society of Hermatology and Oncology in Hannover in October 1989 to provide an up-to-date overv.iew. Leading experts from the United States, Sweden, and Germany reported on the results being obtained with aclacinomycin A, alone or combined with other agents, in patients with acute leukemias and myelodysplastic syndromes. This book is based on their contributions. As regards single-agent treatment, aclacinomycin A in myelodys plastic syndromes is dealt with, as well as its application in older patients with acute myeloid leukemia. Four contributions are devoted to the use of aclacinomycin A in combination with conventional or intermediate dose cytosine arabinoside or etoposide in patients with relapsed or refractory acute myeloid leukemia. The results reported indicate that aclacinomycin A has substantial activity in the treatment of hematologic malignancies. In summary, this book provides a valuable update on the current status of aclacinomycin A as used by experts in the treatment of he matologic malignancies</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hematology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology </subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hematology</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Myelose</subfield><subfield code="0">(DE-588)4170926-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Aclarubicin</subfield><subfield code="0">(DE-588)4243689-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)1071861417</subfield><subfield code="a">Konferenzschrift</subfield><subfield code="y">1989</subfield><subfield code="z">Hannover</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Myelose</subfield><subfield code="0">(DE-588)4170926-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Aclarubicin</subfield><subfield code="0">(DE-588)4243689-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hiddemann, W.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mertelsmann, R.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783540526131</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783642757211</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-3-642-75720-4</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_1990/2004</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031524592</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-3-642-75720-4</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_1990/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | (DE-588)1071861417 Konferenzschrift 1989 Hannover gnd-content |
| genre_facet | Konferenzschrift 1989 Hannover |
| id | DE-604.BV046144407 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:36:25Z |
| institution | BVB |
| isbn | 9783642757204 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031524592 |
| oclc_num | 1119076175 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (IX, 52 p) |
| psigel | ZDB-2-SME ZDB-2-SME_1990/2004 ZDB-2-SME ZDB-2-SME_1990/2004 |
| publishDate | 1990 |
| publishDateSearch | 1990 |
| publishDateSort | 1990 |
| publisher | Springer Berlin Heidelberg |
| record_format | marc |
| spelling | New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia edited by W. Hiddemann, R. Mertelsmann Berlin, Heidelberg Springer Berlin Heidelberg 1990 1 Online-Ressource (IX, 52 p) txt rdacontent c rdamedia cr rdacarrier Since the introduction of new anthracycline derivatives and anthrachi none analogues a few years ago, aclacinomycin A (Aclarubicin) has become an established agent for the treatment of hematologic malig nancies. A special symposium was therefore held during the congress of the German Society of Hermatology and Oncology in Hannover in October 1989 to provide an up-to-date overv.iew. Leading experts from the United States, Sweden, and Germany reported on the results being obtained with aclacinomycin A, alone or combined with other agents, in patients with acute leukemias and myelodysplastic syndromes. This book is based on their contributions. As regards single-agent treatment, aclacinomycin A in myelodys plastic syndromes is dealt with, as well as its application in older patients with acute myeloid leukemia. Four contributions are devoted to the use of aclacinomycin A in combination with conventional or intermediate dose cytosine arabinoside or etoposide in patients with relapsed or refractory acute myeloid leukemia. The results reported indicate that aclacinomycin A has substantial activity in the treatment of hematologic malignancies. In summary, this book provides a valuable update on the current status of aclacinomycin A as used by experts in the treatment of he matologic malignancies Oncology Hematology Oncology Myelose (DE-588)4170926-3 gnd rswk-swf Aclarubicin (DE-588)4243689-8 gnd rswk-swf (DE-588)1071861417 Konferenzschrift 1989 Hannover gnd-content Myelose (DE-588)4170926-3 s Aclarubicin (DE-588)4243689-8 s DE-604 Hiddemann, W. edt Mertelsmann, R. edt Erscheint auch als Druck-Ausgabe 9783540526131 Erscheint auch als Druck-Ausgabe 9783642757211 https://doi.org/10.1007/978-3-642-75720-4 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia Oncology Hematology Oncology Myelose (DE-588)4170926-3 gnd Aclarubicin (DE-588)4243689-8 gnd |
| subject_GND | (DE-588)4170926-3 (DE-588)4243689-8 (DE-588)1071861417 |
| title | New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia |
| title_auth | New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia |
| title_exact_search | New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia |
| title_full | New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia edited by W. Hiddemann, R. Mertelsmann |
| title_fullStr | New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia edited by W. Hiddemann, R. Mertelsmann |
| title_full_unstemmed | New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia edited by W. Hiddemann, R. Mertelsmann |
| title_short | New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia |
| title_sort | new findings on aclarubicin in the treatment of acute myeloid leukemia |
| topic | Oncology Hematology Oncology Myelose (DE-588)4170926-3 gnd Aclarubicin (DE-588)4243689-8 gnd |
| topic_facet | Oncology Hematology Oncology Myelose Aclarubicin Konferenzschrift 1989 Hannover |
| url | https://doi.org/10.1007/978-3-642-75720-4 |
| work_keys_str_mv | AT hiddemannw newfindingsonaclarubicininthetreatmentofacutemyeloidleukemia AT mertelsmannr newfindingsonaclarubicininthetreatmentofacutemyeloidleukemia |